Show simple item record

dc.contributor.authorKudahetti, Sen_US
dc.contributor.authorFisher, Gen_US
dc.contributor.authorAmbroisine, Len_US
dc.contributor.authorFoster, Cen_US
dc.contributor.authorReuter, Ven_US
dc.contributor.authorEastham, Jen_US
dc.contributor.authorMoller, Hen_US
dc.contributor.authorKattan, MWen_US
dc.contributor.authorCooper, CSen_US
dc.contributor.authorScardino, Pen_US
dc.contributor.authorCuzick, Jen_US
dc.contributor.authorBerney, DMen_US
dc.contributor.authorGrp, T-APen_US
dc.date.accessioned2018-08-29T11:10:39Z
dc.date.issued2009-07en_US
dc.identifier1en_US
dc.identifier.citationBJU INTERNATIONAL, 2009, 104 pp. 20 - 24en_US
dc.identifier.issn1464-4096en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2402
dc.identifier.doi10.1111/j.1464-410X.2009.08407.xen_US
dc.description.abstractOBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival ( hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P < 0.001) and overall survival (HR 2.37, 95% CI 1.84-3.05, P < 0.001). In multivariate analysis including competing biological variables p53 expression was still significantly linked to prostate cancer survival (HR 1.51, 95% CI 1.04-2.19, P = 0.03) and overall survival (HR 1.57, 95% CI 1.21-2.05, P = 0.001). CONCLUSIONS We conclude that p53 may have a role in the future assessment of newly diagnosed prostate cancer, as it significantly adds to the current prognostic model.en_US
dc.format.extent20 - 24en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherWILEY-BLACKWELL PUBLISHING, INCen_US
dc.titlep53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate canceren_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/j.1464-410X.2009.08407.xen_US
rioxxterms.licenseref.startdate2009-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBJU INTERNATIONALen_US
pubs.notesaffiliation: Berney, DM (Reprint Author), Royal London Hosp, Queen Marys Sch Med & Dent, Dept Cellular Pathol, 80 Newark St, London E1 2ES, England. Kudahetti, Sak; Berney, Daniel M., Thames Canc Registry, Barts & London Sch Med & Dent, Ctr Mol Oncol, Orchid Tissue Lab, London, England. Fisher, Gabrielle; Ambroisine, Laurence; Cuzick, Jack, Thames Canc Registry, Canc Res UK Ctr Epidemiol Math & Stat, Wolfson Inst Prevent Med, London, England. Moller, Henrik, Thames Canc Registry, Kings Coll London, London, England. Foster, Christopher, Liverpool Univ Hosp, Dept Cellular Pathol & Mol Genet, Liverpool, Merseyside, England. Cooper, Colin S., Royal Marsden Hosp, Inst Canc, Sutton, Surrey, England. Reuter, Victor, Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. Eastham, James; Scardino, Peter, Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA. Kattan, Michael W., Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. keywords: biomarker; Gleason; prostate cancer; p53; watchful waiting keywords-plus: RADIATION-THERAPY; PROTEIN EXPRESSION; BCL-2; KI-67; RECURRENCE; MUTATIONS; DIAGNOSIS; SURVIVAL; MEN; PROLIFERATION research-areas: Urology & Nephrology web-of-science-categories: Urology & Nephrology author-email: danberney@hotmail.com orcid-numbers: Moller, Henrik/0000-0001-8200-5929 Berney, Daniel/0000-0001-5474-8696 funding-acknowledgement: Cancer Research UK; The National Institute of Health (SPORE); The Koch Foundation; NCRI; Grand Charity of Freemasons; Orchid Appeal; Medical Research Council [G0501019] funding-text: This work was supported by Cancer Research UK, The National Institute of Health (SPORE), The Koch Foundation, The NCRI and the Grand Charity of Freemasons. D. B. and S. K. are supported by The Orchid Appeal. number-of-cited-references: 27 times-cited: 26 usage-count-last-180-days: 0 usage-count-since-2013: 2 journal-iso: BJU Int. doc-delivery-number: 456TM unique-id: ISI:000266874000005 oa: gold_or_bronze da: 2018-08-29en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cell Transformation
pubs.volume104en_US
pubs.embargo.termsNot knownen_US
icr.researchteamCell Transformationen_US
dc.contributor.icrauthorCooper, Colinen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record